Impact of Infliximab-dyyb (Infliximab Biosimilar) on Clinical and Patient-Reported Outcomes: 1-Year Follow-up Results from an Observational Real-World Study Among Patients with Inflammatory Bowel Disease in the US and Canada (the ONWARD Study)

Bincy Abraham, Bertus Eksteen, Khan Nedd, Hrishikesh Kale, Dipen Patel, Jennifer Stephens, Ahmed Shelbaya, Richard Chambers, Arif Soonasra, Bincy Abraham, Bertus Eksteen, Khan Nedd, Hrishikesh Kale, Dipen Patel, Jennifer Stephens, Ahmed Shelbaya, Richard Chambers, Arif Soonasra

Abstract

Introduction: To date, there are limited real-world studies published on the use of infliximab-dyyb, a biosimilar to reference product (RP) infliximab approved for the treatment of moderate to severe inflammatory bowel disease (IBD), including Crohn's disease (CD) and ulcerative colitis (UC) in North America. This study examined utilization patterns and the effects of infliximab-dyyb on clinical outcomes, patient-reported outcomes (PROs), and healthcare resource use (HCRU) in IBD patients in a real-world setting.

Methods: In this prospective, observational study, adult IBD patients in the US and Canada were recruited to initiate treatment with infliximab-dyyb and followed for 12 months. Patients included biologic-naïve users of infliximab-dyyb and patients switching from RP infliximab or other biologics to infliximab-dyyb. Partial Mayo (pMAYO) and Harvey Bradshaw Index (HBI) scores measured clinical outcomes for the UC and CD cohorts, respectively. Key PRO measures included the SIBDQ, EQ-VAS, and psychological outcomes. In addition, work productivity, HCRU, and adverse events (AEs) were assessed.

Results: A total of 67 CD and 48 UC patients were enrolled (51% female; mean age 44 years; 87% Caucasian; mean BMI 27.9). Thirty-nine patients were biologic-naïve, 57 switched from RP infliximab, and 19 switched from other biologics. Among UC biologic-naïve users, pMAYO decreased from 5.67 to 1.09 (p < 0.0001) and the remission rate increased from 5.6 to 90.9% (p = 0.0015). For UC patients switching from RP infliximab, pMAYO decreased from 1.38 to 0.29 (p = 0.0103). For CD biologic-naïve users, HBI scores and remission rates did not significantly change. The scores on all the PROs significantly improved from baseline to 12 months. A total of 22 AEs occurred consistent with the known AE profile for infliximab.

Conclusions: Clinical outcomes among biologic-naïve users of infliximab-dyyb improved for UC and were maintained for CD patients. Biologic-naïve users of infliximab-dyyb showed significant improvements in PROs. Patients switching from RP infliximab to infliximab-dyyb maintained their clinical outcomes and PROs.

Trial registration: ClinicalTrials.gov Registration Number: NCT03801928 (February 23, 2018).

Keywords: Biosimilars; Exploratory Treatment Effectiveness Study; Inflammatory bowel disease; Infliximab; Real-world outcomes.

© 2022. The Author(s).

Figures

Fig. 1
Fig. 1
Patient selection in this study
Fig. 2
Fig. 2
Changes from baseline in SIBDQ and EQ-VAS scores. *Denotes statistically significant (p < 0.05) change from mixed model for repeated measures (MMRM). EQ-VAS EuroQol Visual Analogue Scale, IBD inflammatory bowel disease, SIBDQ Short Inflammatory Bowel Disease Questionnaire
Fig. 3
Fig. 3
Changes from baseline in daily impairment (WPAI), effectiveness (TSQM), PHQ-8, GAD-7. *Denotes statistically significant (p < 0.05) change from mixed model for repeated measures (MMRM). IBD inflammatory bowel disease, SIBDQ Short Inflammatory Bowel Disease Questionnaire, EQ-VAS EuroQol Visual Analogue Scale

References

    1. Hazel K, O’Connor A. Emerging treatments for inflammatory bowel disease. Ther Adv Chronic Dis. 2020;11:2040622319899297. doi: 10.1177/2040622319899297.
    1. Hanauer SB, et al. Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial. Lancet. 2002;359(9317):1541–1549. doi: 10.1016/S0140-6736(02)08512-4.
    1. Rutgeerts P, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005;353(23):2462–2476. doi: 10.1056/NEJMoa050516.
    1. Sands BE, et al. Infliximab maintenance therapy for fistulizing Crohn’s disease. N Engl J Med. 2004;350(9):876–885. doi: 10.1056/NEJMoa030815.
    1. Sands BE, et al. Long-term treatment of rectovaginal fistulas in Crohn’s disease: response to infliximab in the ACCENT II study. Clin Gastroenterol Hepatol. 2004;2(10):912–920. doi: 10.1016/S1542-3565(04)00414-8.
    1. Veloz MFG, et al. Long-term follow up after switching from original infliximab to an infliximab biosimilar: real-world data. Ther Adv Gastroenterol. 2019;12:1756284819858052–1756284819858052.
    1. Kapoor S, et al. Real-life tolerability and effectiveness of adalimumab biosimilar in ankylosing spondylitis: the adalimumab biosimilar patient registry data. ACR Open Rheumatol. 2019;1(8):480–484. doi: 10.1002/acr2.11067.
    1. FDA approves Inflectra, a biosimilar to Remicade. 2016..
    1. Martín-Gutiérrez N, Sánchez-Hernández JG, Rebollo N, Pordomingo AF, Muñoz F, Otero MJ. Long-term effectiveness and pharmacokinetics of the infliximab biosimilar CT-P13 after switching from the originator during the treatment of inflammatory bowel disease [published online ahead of print, 2020 Oct 28]. Eur J Hosp Pharm. 2020. 10.1136/ejhpharm-2020-002410.
    1. Sagami S, et al. Post-marketing analysis for biosimilar CT-P13 in inflammatory bowel disease compared with external data of originator infliximab in Japan. J Gastroenterol Hepatol. 2021;36(8):2091–2100. doi: 10.1111/jgh.15399.
    1. Farkas K, et al. Efficacy of the new infliximab biosimilar CT-P13 induction therapy in Crohn’s disease and ulcerative colitis—experiences from a single center. Expert Opin Biol Ther. 2015;15(9):1257–1262. doi: 10.1517/14712598.2015.1064893.
    1. Gecse KB, et al. Efficacy and safety of the biosimilar infliximab CT-P13 treatment in inflammatory bowel diseases: a prospective, multicentre, Nationwide Cohort. J Crohns Colitis. 2016;10(2):133–140. doi: 10.1093/ecco-jcc/jjv220.
    1. Jung YS, et al. Efficacy and safety of CT-P13, a biosimilar of infliximab, in patients with inflammatory bowel disease: a retrospective multicenter study. J Gastroenterol Hepatol. 2015;30(12):1705–1712. doi: 10.1111/jgh.12997.
    1. Kang YS, et al. Clinical experience of the use of CT-P13, a biosimilar to infliximab in patients with inflammatory bowel disease: a case series. Dig Dis Sci. 2015;60(4):951–956. doi: 10.1007/s10620-014-3392-z.
    1. Nikiphorou E, et al. Clinical effectiveness of CT-P13 (Infliximab biosimilar) used as a switch from Remicade (infliximab) in patients with established rheumatic disease. Report of clinical experience based on prospective observational data. Expert Opin Biol Ther. 2015;15(12):1677–1683. doi: 10.1517/14712598.2015.1103733.
    1. Smits LJ, et al. Clinical outcomes following a switch from Remicade® to the biosimilar CT-P13 in inflammatory bowel disease patients: a prospective observational cohort study. J Crohns Colitis. 2016;10(11):1287–1293. doi: 10.1093/ecco-jcc/jjw087.
    1. Tanaka Y, et al. Safety and efficacy of CT-P13 in Japanese patients with rheumatoid arthritis in an extension phase or after switching from infliximab. Mod Rheumatol. 2017;27(2):237–245. doi: 10.1080/14397595.2016.1206244.
    1. Desai RJ, Kim SC, Curtis JR, et al. Methodologic considerations for noninterventional studies of switching from reference biologic to biosimilars. Pharmacoepidemiol Drug Saf. 2020;29(7):757–769. doi: 10.1002/pds.4809.
    1. Komaki Y, et al. Systematic review with meta-analysis: the efficacy and safety of CT-P13, a biosimilar of anti-tumour necrosis factor-α agent (infliximab), in inflammatory bowel diseases. Aliment Pharmacol Ther. 2017;45(8):1043–1057. doi: 10.1111/apt.13990.
    1. Ratnakumaran R, et al. Efficacy and tolerability of initiating, or switching to, infliximab biosimilar CT-P13 in inflammatory bowel disease (IBD): a large single-centre experience. Scand J Gastroenterol. 2018;53(6):700–707. doi: 10.1080/00365521.2018.1464203.
    1. Kaniewska M, Moniuszko A, Rydzewska G. The efficacy and safety of the biosimilar product (Inflectra(®)) compared to the reference drug (Remicade(®)) in rescue therapy in adult patients with ulcerative colitis. Prz Gastroenterol. 2017;12(3):169–174.
    1. Høivik ML, et al. Switching from originator to biosimilar infliximab—real world data of a prospective 18 months follow-up of a single-centre IBD population. Scand J Gastroenterol. 2018;53(6):692–699. doi: 10.1080/00365521.2018.1463391.
    1. Veloz MFG, et al. Switching from reference infliximab to CT-P13 in patients with inflammatory bowel disease: results of a multicenter study after 12 months. Rev Esp Enferm Dig. 2018;110(9):564–570. doi: 10.17235/reed.2018.5368/2017.
    1. Armuzzi A, et al. The PROSIT cohort of infliximab biosimilar in IBD: a prolonged follow-up on the effectiveness and safety across Italy. Inflamm Bowel Dis. 2019;25(3):568–579. doi: 10.1093/ibd/izy264.
    1. Meyer A, et al. Effectiveness and safety of reference infliximab and biosimilar in Crohn disease: A French Equivalence Study. Ann Intern Med. 2019;170(2):99–107. doi: 10.7326/M18-1512.
    1. Bronswijk M, et al. Evaluating efficacy, safety, and pharmacokinetics after switching from infliximab originator to biosimilar CT-P13: experience from a large tertiary referral center. Inflamm Bowel Dis. 2020;26(4):628–634.
    1. Ebada MA, et al. An updated systematic review and meta-analysis about the safety and efficacy of infliximab biosimilar, CT-P13, for patients with inflammatory bowel disease. Int J Colorectal Dis. 2019;34(10):1633–1652. doi: 10.1007/s00384-019-03354-7.
    1. Gheorghe C, Svoboda P, Mateescu B. Effectiveness and safety of biosimilar infliximab (CT-P13) in a real-life setting in patients with Crohn’s disease or ulcerative colitis. J Drug Assess. 2019;8(1):129–134. doi: 10.1080/21556660.2019.1626735.
    1. Guerra Veloz MF, et al. Loss of efficacy and safety of the switch from infliximab original to infliximab biosimilar (CT-P13) in patients with inflammatory bowel disease. World J Gastroenterol. 2018;24(46):5288–5296. doi: 10.3748/wjg.v24.i46.5288.
    1. Ho SL, et al. Effectiveness of switching from reference product Infliximab to Infliximab-Dyyb in patients with inflammatory bowel disease in an integrated healthcare system in the United States: a retrospective, propensity score-matched, non-inferiority cohort study. BioDrugs. 2020;34(3):395–404. doi: 10.1007/s40259-020-00409-y.
    1. Ilias A, et al. Outcomes of patients with inflammatory bowel diseases switched from maintenance therapy with a biosimilar to remicade. Clin Gastroenterol Hepatol. 2019;17(12):2506–2513.e2. doi: 10.1016/j.cgh.2018.12.036.
    1. Jørgensen KK, et al. Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial. Lancet. 2017;389(10086):2304–2316. doi: 10.1016/S0140-6736(17)30068-5.
    1. Kim NH, et al. Long-term efficacy and safety of CT-P13, a biosimilar of infliximab, in patients with inflammatory bowel disease: a retrospective multicenter study. J Gastroenterol Hepatol. 2019;34(9):1523–1532. doi: 10.1111/jgh.14645.
    1. Nakagawa T, et al. Infliximab biosimilar CT-P13 is interchangeable with its originator for patients with inflammatory bowel disease in real world practice. Intest Res. 2019;17(4):504–515. doi: 10.5217/ir.2019.00030.
    1. Petitdidier N, et al. Patients’ perspectives after switching from infliximab to biosimilar CT-P13 in patients with inflammatory bowel disease: a 12-month prospective cohort study. Dig Liver Dis. 2019;51(12):1652–1660. doi: 10.1016/j.dld.2019.08.020.
    1. Plevris N, et al. Implementation of CT-P13 via a managed switch programme in Crohn’s disease: 12-month real-world outcomes. Dig Dis Sci. 2019;64(6):1660–1667. doi: 10.1007/s10620-018-5406-8.
    1. Strik AS, et al. Serum concentrations after switching from originator infliximab to the biosimilar CT-P13 in patients with quiescent inflammatory bowel disease (SECURE): an open-label, multicentre, phase 4 non-inferiority trial. Lancet Gastroenterol Hepatol. 2018;3(6):404–412. doi: 10.1016/S2468-1253(18)30082-7.
    1. van Hoeve K, et al. Efficacy, pharmacokinetics, and immunogenicity is not affected by switching from infliximab originator to a biosimilar in pediatric patients with inflammatory bowel disease. Ther Drug Monit. 2019;41(3):317–324. doi: 10.1097/FTD.0000000000000601.
    1. Ye BD, et al. Efficacy and safety of biosimilar CT-P13 compared with originator infliximab in patients with active Crohn’s disease: an international, randomised, double-blind, phase 3 non-inferiority study. Lancet. 2019;393(10182):1699–1707. doi: 10.1016/S0140-6736(18)32196-2.
    1. Chaparro M, et al. Effectiveness and safety of the switch from Remicade® to CT-P13 in patients with inflammatory bowel disease. J Crohns Colitis. 2019;13(11):1380–1386. doi: 10.1093/ecco-jcc/jjz070.
    1. Reinisch W, et al. Long-term infliximab maintenance therapy for ulcerative colitis: the ACT-1 and-2 extension studies. Inflamm Bowel Dis. 2012;18(2):201–211. doi: 10.1002/ibd.21697.
    1. Sandborn WJ, et al. One-year maintenance outcomes among patients with moderately-to-severely active ulcerative colitis who responded to induction therapy with adalimumab: subgroup analyses from ULTRA 2. Aliment Pharmacol Ther. 2013;37(2):204–213. doi: 10.1111/apt.12145.
    1. Vermeire S, et al. Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn’s disease. Gut. 2007;56(9):1226–1231. doi: 10.1136/gut.2006.099978.
    1. Yoshida K, et al. Scheduled infliximab monotherapy to prevent recurrence of Crohn’s disease following ileocolic or ileal resection: a 3-year prospective randomized open trial. Inflamm Bowel Dis. 2012;18(9):1617–1623. doi: 10.1002/ibd.21928.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe